Brian Elsbernd - 11 Nov 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Compliance/Legal Officer
Signature
/s/ Brian Elsbernd
Issuer symbol
CPRX
Transactions as of
11 Nov 2022
Net transactions value
-$86,253
Form type
4
Filing time
15 Nov 2022, 16:00:59 UTC
Previous filing
16 Feb 2022
Next filing
08 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Sale $238,103 -14,666 -57% $16.24 11,096 11 Nov 2022 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $120,250 +65,000 +586% $1.85* 76,096 14 Nov 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Options Exercise $31,600 +40,000 +53% $0.7900* 116,096 14 Nov 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -65,000 -6.8% $0.000000 885,667 14 Nov 2022 Common Stock 65,000 $1.85 Direct F3
transaction CPRX Options to purchase common stock Options Exercise $0 -40,000 -4.5% $0.000000 845,667 14 Nov 2022 Common Stock 40,000 $0.7900 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons and to raise funds for option exercises and not as a result of any disagreement with the Registrant. Mr. Elsbernd remains an officer of the Company.
F2 Shares were sold in various lots from $16.23 to $16.265 per share. Price shown represents a weighted average sale price.
F3 Options vested in three equal tranches on February 16, 2017, 2018 and 2019.
F4 Options vested in two equal tranches on June 15, 2017 and 2018.